This allows for the generation of conceivably less immunogenic CAR T cells, which have been shown to induce remission of ALL refractory to previous murine-scFv-based anti-CD19-CAR T cell therapy [66]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.